Gsk PLC

GSK plc, a 10% owner and director, acquired an additional 1.47 million ordinary shares of Wave Life Sciences Ltd. for $19 per share, increasing its total beneficial ownership to over 18.2 million shares.

GSK plc reports acquiring additional ordinary shares of Wave Life Sciences Ltd., increasing its beneficial ownership.

GSK plc reported 13 holdings worth $602.2M for the period ended June 30, 2026.

GSK plc has filed its quarterly 13F holdings report, detailing its equity investments as of March 31, 2026.

GSK plc filed its Form 13F-HR, revealing its equity holdings totaling approximately $799 million as of December 31, 2025, across 15 distinct positions.

GSK plc has completed the divestment of its entire stake in CureVac N.V. through a tender offer, ceasing to be a beneficial owner.

GSK plc's subsidiary, Glaxo Group Limited, has agreed to tender its 7.4% stake in CureVac N.V. into BioNTech SE's exchange offer.

GSK PLC has filed an Amendment No. 9 to its Schedule 13D, reporting a decrease in its beneficial ownership of Spero Therapeutics, Inc. common stock to 16.4% due to an increase in Spero's outstanding shares.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 5.8% of GSK PLC's common stock as of March 31, 2026.

BlackRock, Inc. has filed an amended Schedule 13G, reporting an 8.9% beneficial ownership stake in GSK plc as of December 31, 2024, held for investment purposes.